Νορβηγία - Νορβηγικά - Statens legemiddelverk

baxter medical ab - glukosemonohydrat / natriumklorid / kaliumklorid / magnesiumkloridheksahydrat / natriumacetattrihydrat / natriumglukonat - infusjonsvæske, oppløsning - 50 mg/ ml / 5.26 mg/ ml / 0.37 mg/ ml / 0.3 mg/ ml / 3.68 mg/ ml / 5.02 mg/ ml

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - pegfilgrastim - nøytropeni - immunostimulants, , koloni stimulerende faktorer - reduksjon i varigheten av nøytropeni og forekomsten av febril nøytropeni hos voksne pasienter behandlet med cytotoksiske kjemoterapi for kreft (med unntak av kronisk myelogen leukemi og aml syndromer).

Νορβηγία - Νορβηγικά - Statens legemiddelverk

sintetica gmbh - efedrinhydroklorid - injeksjonsvæske, oppløsning - 50 mg/ ml

Νορβηγία - Νορβηγικά - Statens legemiddelverk

orifarm as - blinatumomab - pulver til konsentrat og oppløsning til infusjonsvæske, oppløsning - 38.5 mikrog

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibakterielle midler for systemisk bruk, - doribax er angitt for behandling av følgende infeksjoner hos voksne:nosokomiale lungebetennelse (inkludert ventilator-forbundet lungebetennelse);komplisert intra-abdominal infeksjoner;kompliserte urinveisinfeksjoner. det bør vurderes å offisielle retningslinjer for riktig bruk av antibakterielle midler.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunsuppressive - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasis - immunsuppressive - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Νορβηγία - Νορβηγικά - Statens legemiddelverk

laboratoire aguettant - adrenalintartrat - injeksjonsvæske, oppløsning i ferdigfylt sprøyte - 0.1 mg/ ml

Νορβηγία - Νορβηγικά - Statens legemiddelverk

n.v. organon - kloosterstraat - ezetimib - tablett - 10 mg

Νορβηγία - Νορβηγικά - Statens legemiddelverk

n.v. organon - kloosterstraat - ezetimib / simvastatin - tablett - 10 mg / 20 mg